{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T23:58:34Z","timestamp":1795132714601,"version":"4.10.3"},"reference-count":124,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"unspecified","delay-in-days":19,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["bmjmed"],"accepted":{"date-parts":[[2026,7,23]]},"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:p>Asthma and chronic obstructive pulmonary disease (COPD) are highly prevalent heterogeneous airway diseases in which a subset of patients with severe disease have a disproportionate share of morbidity and mortality, largely through exacerbations. Major immunological advances have reframed both conditions around endotypes, with type 2 (inflammation driven by type 2 helper cells and group 2 innate lymphoid cells) and other inflammatory pathways defined and targeted with biological treatments. This review provides an overview of biological treatments in asthma and COPD. Biological treatments are engineered monoclonal antibodies targeting proteins (eg, IgE, interleukin (IL) 5 and IL5 receptor, IL4 and IL13, and upstream epithelial alarmins, such as thymic stromal lymphopoietin (TSLP) and IL33) that enable precision treatment. Biological treatments consistently reduce exacerbations and improve lung function and quality of life in biomarker defined populations. In asthma, short term biomarkers (blood eosinophils, fractional exhaled nitric oxide (FeNO), and sputum eosinophils) guide selection, whereas emerging longer term markers, including transcriptomic signatures and imaging endpoints, offer mechanistic readouts and raise the prospect of disease modification. In COPD, type 2 biological medicines have yielded benefits among patients with high levels of eosinophils and who are prone to exacerbations, and anti-IL33 and TSLP treatments show mixed but intriguing signals. Blood eosinophil counts (\u2265300\u2009cells\/\u00b5L) remain the most robust predictor of benefit; FeNO may provide complementary categorisation in select settings. Priorities for treatment are identifying treatable traits, supporting comprehensive self-management, and timely referral for patients with exacerbations despite optimised inhaled treatment. Key gaps include head-to-head comparisons, criteria for switching or stopping biological medicines, feasibility of de-escalation of inhaled treatment, and type 2 low strategies.<\/jats:p>","DOI":"10.1136\/bmjmed-2025-002195","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:50:15Z","timestamp":1787244615000},"page":"e002195","source":"Crossref","is-referenced-by-count":1,"title":["Biological treatments for asthma and chronic obstructive pulmonary disease"],"prefix":"10.1136","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2100-6148","authenticated-orcid":false,"given":"Vickram","family":"Tejwani","sequence":"first","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Integrated Hospital Care Institute, Cleveland Clinic, Cleveland, OH, USA"},{"name":"Department of Genomic Sciences and Systems Biology, Cleveland Clinic Research, Cleveland Clinic, Cleveland, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trishul","family":"Siddharthan","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, University of Miami, Coral Gables, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uddalak","family":"Majumdar","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine, Integrated Hospital Care Institute, Cleveland, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0863-6471","authenticated-orcid":false,"given":"Umur","family":"Hatipo\u011flu","sequence":"additional","affiliation":[{"name":"Respiratory Institute, Cleveland Clinic, Cleveland, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola A","family":"Hanania","sequence":"additional","affiliation":[{"name":"Section of Pulmonary and Critical Care Medicine, Baylor College of Medicine, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"key":"2026082009500867000_5.1.e002195.1","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.103051","article-title":"Global, regional, national burden of asthma from 1990 to 2021, with projections of incidence to 2050: a systematic analysis of the global burden of disease study 2021","volume":"80","author":"Yuan","year":"2025","journal-title":"EClinicalMedicine"},{"key":"2026082009500867000_5.1.e002195.2","doi-asserted-by":"crossref","DOI":"10.1186\/s12931-024-03051-2","article-title":"Global, regional, and national burden of chronic obstructive pulmonary disease and its attributable risk factors from 1990 to 2021: an analysis for the Global Burden of Disease Study 2021","volume":"26","author":"Wang","year":"2025","journal-title":"Respir Res"},{"key":"2026082009500867000_5.1.e002195.3","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.molmed.2022.09.001","article-title":"Asthma exacerbations: the Achilles heel of asthma care","volume":"28","author":"McIntyre","year":"2022","journal-title":"Trends Mol Med"},{"key":"2026082009500867000_5.1.e002195.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2006.01.033"},{"key":"2026082009500867000_5.1.e002195.5","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201703-259OC"},{"key":"2026082009500867000_5.1.e002195.6","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02469-2022"},{"key":"2026082009500867000_5.1.e002195.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1411863"},{"key":"2026082009500867000_5.1.e002195.8","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/j.1365-2222.2005.02191.x","article-title":"Anti\u2010immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti\u2010inflammatory activity and clinical efficacy","volume":"35","author":"Holgate","year":"2005","journal-title":"Clin Experimental Allergy"},{"key":"2026082009500867000_5.1.e002195.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2016.05.011"},{"key":"2026082009500867000_5.1.e002195.10","doi-asserted-by":"crossref","DOI":"10.1186\/s12890-025-03898-1","article-title":"Progression from GOLD A\/B to GOLD E: a claims analysis of patients with COPD newly initiating inhaled therapy","volume":"25","author":"Siddharthan","year":"2025","journal-title":"BMC Pulm Med"},{"key":"2026082009500867000_5.1.e002195.11","doi-asserted-by":"crossref","first-page":"107629","DOI":"10.1016\/j.rmed.2024.107629","article-title":"Frequency and economic burden of exacerbations in inhaled corticosteroid\/long-acting beta-agonist-treated patients with asthma: A retrospective US claims study","volume":"226","author":"Duh","year":"2024","journal-title":"Respir Med"},{"key":"2026082009500867000_5.1.e002195.12","doi-asserted-by":"crossref","first-page":"S98","DOI":"10.1513\/AnnalsATS.201711-868MG","article-title":"Interleukin-13 Stimulation Reveals the Cellular and Functional Plasticity of the Airway Epithelium","volume":"15","author":"Seibold","year":"2018","journal-title":"Ann Am Thorac Soc"},{"key":"2026082009500867000_5.1.e002195.13","doi-asserted-by":"crossref","first-page":"00309","DOI":"10.1183\/23120541.00309-2020","article-title":"Identification and treatment of T2-low asthma in the era of biologics","volume":"7","author":"Kyriakopoulos","year":"2021","journal-title":"ERJ Open Res"},{"key":"2026082009500867000_5.1.e002195.14","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/j.jaip.2025.04.055","article-title":"Diagnosis and Treatment Options for T2-Low Asthma","volume":"13","author":"Thomas","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2026082009500867000_5.1.e002195.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2010.11.037"},{"key":"2026082009500867000_5.1.e002195.16","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41577-018-0006-6","article-title":"Targeting cytokines to treat asthma and chronic obstructive pulmonary disease","volume":"18","author":"Barnes","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"2026082009500867000_5.1.e002195.17","doi-asserted-by":"crossref","DOI":"10.1177\/2040622321995691","article-title":"The spectrum of clinical sequelae associated with alpha-1 antitrypsin deficiency","volume":"12_suppl","author":"Tejwani","year":"2021","journal-title":"Ther Adv Chronic Dis"},{"key":"2026082009500867000_5.1.e002195.18","doi-asserted-by":"crossref","DOI":"10.1183\/20734735.0229-2023","article-title":"Type 2 inflammation in COPD: is it just asthma?","volume":"20","author":"Beech","year":"2024","journal-title":"Breathe (Sheff)"},{"key":"2026082009500867000_5.1.e002195.19","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2019.00282","article-title":"Prevalence and Baseline Clinical Characteristics of Eosinophilic Chronic Obstructive Pulmonary Disease: A Meta-Analysis and Systematic Review","volume":"6","author":"Wu","year":"2019","journal-title":"Front Med (Lausanne)"},{"key":"2026082009500867000_5.1.e002195.20","doi-asserted-by":"crossref","DOI":"10.1038\/s41533-025-00425-x","article-title":"BTS\/NICE\/SIGN guideline for asthma 2024: Diagnosis, monitoring and chronic asthma management. How does this compare to GINA 2024?","volume":"35","author":"Gruffydd-Jones","year":"2025","journal-title":"NPJ Prim Care Respir Med"},{"key":"2026082009500867000_5.1.e002195.21","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00202013"},{"key":"2026082009500867000_5.1.e002195.22","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1016\/S2213-2600(25)00242-5","article-title":"2025 GINA report for asthma","volume":"13","author":"Venkatesan","year":"2025","journal-title":"Lancet Respir Med"},{"key":"2026082009500867000_5.1.e002195.23","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2001.117880"},{"key":"2026082009500867000_5.1.e002195.24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009705"},{"key":"2026082009500867000_5.1.e002195.25","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-154-9-201105030-00002"},{"key":"2026082009500867000_5.1.e002195.26","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(94)90036-1"},{"key":"2026082009500867000_5.1.e002195.27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1403290"},{"key":"2026082009500867000_5.1.e002195.28","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1056\/NEJMoa2406673","article-title":"Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype","volume":"391","author":"Jackson","year":"2024","journal-title":"N Engl J Med"},{"key":"2026082009500867000_5.1.e002195.29","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31324-1"},{"key":"2026082009500867000_5.1.e002195.30","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials","volume":"3","author":"Castro","year":"2015","journal-title":"Lancet Respir Med"},{"key":"2026082009500867000_5.1.e002195.31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804092"},{"key":"2026082009500867000_5.1.e002195.32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034975"},{"key":"2026082009500867000_5.1.e002195.33","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S2213-2600(26)00076-7","article-title":"Efficacy and safety of tezepelumab versus placebo in reducing oral corticosteroid use in adults with severe, oral corticosteroid-dependent asthma (SUNRISE): a multicentre, placebo-controlled, double-blind, phase 3 trial","volume":"14","author":"Wechsler","year":"2026","journal-title":"Lancet Respir Med"},{"key":"2026082009500867000_5.1.e002195.34","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2025.101107","article-title":"Discontinuation of biologic therapy in severe asthma: Evidence and strategies for safe withdrawal: A scoping review","volume":"18","author":"Ramirez-Villamizar","year":"2025","journal-title":"World Allergy Organ J"},{"key":"2026082009500867000_5.1.e002195.35","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3390\/arm92020014","article-title":"Advancing Care in Severe Asthma: The Art of Switching Biologics","volume":"92","author":"Dragonieri","year":"2024","journal-title":"Adv Respir Med"},{"key":"2026082009500867000_5.1.e002195.36","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-024-01368-y"},{"key":"2026082009500867000_5.1.e002195.37","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S2213-2600(24)00362-X","article-title":"Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomised, double-blind, placebo-controlled, phase 4 trial","volume":"13","author":"Castro","year":"2025","journal-title":"Lancet Respir Med"},{"key":"2026082009500867000_5.1.e002195.38","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300135","article-title":"Tezepelumab and Mucus Plugs in Patients with Moderate-to-Severe Asthma","volume":"2","author":"Nordenmark","year":"2023","journal-title":"NEJM Evid"},{"key":"2026082009500867000_5.1.e002195.39","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1016\/S2213-2600(24)00413-2","article-title":"GOLD COPD report: 2025 update","volume":"13","author":"Venkatesan","year":"2025","journal-title":"Lancet Respir Med"},{"key":"2026082009500867000_5.1.e002195.40","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1111\/all.15056","article-title":"From DREAM to REALITI-A and beyond: Mepolizumab for the treatment of eosinophil-driven diseases","volume":"77","author":"Pavord","year":"2022","journal-title":"Allergy"},{"key":"2026082009500867000_5.1.e002195.41","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.chest.2019.04.012","article-title":"Stability of the Blood Eosinophilic Phenotype in Stable and Exacerbated COPD","volume":"156","author":"Schumann","year":"2019","journal-title":"Chest"},{"key":"2026082009500867000_5.1.e002195.42","doi-asserted-by":"publisher","DOI":"10.1177\/2040622315609251"},{"key":"2026082009500867000_5.1.e002195.43","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2009-0220TR"},{"key":"2026082009500867000_5.1.e002195.44","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201104-0597OC"},{"key":"2026082009500867000_5.1.e002195.45","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.jaip.2023.01.011","article-title":"Treatable Traits in Airway Disease: From Theory to Practice","volume":"11","author":"Agusti","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2026082009500867000_5.1.e002195.46","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2019-214484"},{"key":"2026082009500867000_5.1.e002195.47","doi-asserted-by":"crossref","first-page":"591","DOI":"10.2147\/COPD.S153694","article-title":"Mixed Th2 and non-Th2 inflammatory pattern in the asthma-COPD overlap: a network approach","volume":"13","author":"de Llano","year":"2018","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2026082009500867000_5.1.e002195.48","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/17476348.2020.1804364","article-title":"Endo-phenotyping of COPD patients","volume":"15","author":"Barnes","year":"2021","journal-title":"Expert Rev Respir Med"},{"key":"2026082009500867000_5.1.e002195.49","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303951"},{"key":"2026082009500867000_5.1.e002195.50","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2401304"},{"key":"2026082009500867000_5.1.e002195.51","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1608969"},{"key":"2026082009500867000_5.1.e002195.52","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S2213-2600(24)00409-0","article-title":"Dupilumab for chronic obstructive pulmonary disease with type 2 inflammation: a pooled analysis of two phase 3, randomised, double-blind, placebo-controlled trials","volume":"13","author":"Bhatt","year":"2025","journal-title":"Lancet Respir Med"},{"key":"2026082009500867000_5.1.e002195.53","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708208"},{"key":"2026082009500867000_5.1.e002195.54","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.2147\/COPD.S294333","article-title":"Mepolizumab for Eosinophil-Associated COPD: Analysis of METREX and METREO","volume":"16","author":"Pavord","year":"2021","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2026082009500867000_5.1.e002195.55","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2413181"},{"key":"2026082009500867000_5.1.e002195.56","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/S2213-2600(14)70187-0","article-title":"Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study","volume":"2","author":"Brightling","year":"2014","journal-title":"Lancet Respir Med"},{"key":"2026082009500867000_5.1.e002195.57","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJMoa1905248","article-title":"Benralizumab for the Prevention of COPD Exacerbations","volume":"381","author":"Criner","year":"2019","journal-title":"N Engl J Med"},{"key":"2026082009500867000_5.1.e002195.58","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S2213-2600(19)30338-8","article-title":"Predicting response to benralizumab in chronic obstructive pulmonary disease: analyses of GALATHEA and TERRANOVA studies","volume":"8","author":"Criner","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2026082009500867000_5.1.e002195.59","unstructured":"AstraZeneca . Update on the resolute phase iii trial for fasenra in chronic obstructive pulmonary disease. 2025. Available: https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2025\/update-on-resolute-phase-iii-trial.html"},{"key":"2026082009500867000_5.1.e002195.60","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20172049"},{"key":"2026082009500867000_5.1.e002195.61","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S2213-2600(24)00324-2","article-title":"Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trial","volume":"13","author":"Singh","year":"2025","journal-title":"Lancet Respir Med"},{"key":"2026082009500867000_5.1.e002195.62","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/S2213-2600(21)00167-3","article-title":"Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial","volume":"9","author":"Rabe","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2026082009500867000_5.1.e002195.63","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00718-2023","article-title":"AERIFY-1\/2: two phase 3, randomised, controlled trials of itepekimab in former smokers with moderate-to-severe COPD","volume":"10","author":"Rabe","year":"2024","journal-title":"ERJ Open Res"},{"key":"2026082009500867000_5.1.e002195.64","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02231-2024"},{"key":"2026082009500867000_5.1.e002195.65","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1016\/S0140-6736(26)00637-9","article-title":"Safety and efficacy of astegolimab for COPD with frequent exacerbations regardless of baseline blood eosinophil counts (ALIENTO and ARNASA): randomised, double-blind, placebo-controlled, phase 2b and 3 trials","volume":"407","author":"Papi","year":"2026","journal-title":"Lancet"},{"key":"2026082009500867000_5.1.e002195.66","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13216339","article-title":"Personalized COPD Care: The Future of Precision-Based Therapies","volume":"13","author":"Appleton","year":"2024","journal-title":"J Clin Med"},{"key":"2026082009500867000_5.1.e002195.67","doi-asserted-by":"crossref","DOI":"10.1186\/s12931-017-0633-7","article-title":"A randomised, placebo-controlled trial of anti-interleukin-1 receptor 1 monoclonal antibody MEDI8968 in chronic obstructive pulmonary disease","volume":"18","author":"Calverley","year":"2017","journal-title":"Respir Res"},{"key":"2026082009500867000_5.1.e002195.68","doi-asserted-by":"publisher","DOI":"10.1159\/000117386"},{"key":"2026082009500867000_5.1.e002195.69","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200501-147OC"},{"key":"2026082009500867000_5.1.e002195.70","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200607-995OC"},{"key":"2026082009500867000_5.1.e002195.71","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S137578"},{"key":"2026082009500867000_5.1.e002195.72","doi-asserted-by":"crossref","first-page":"109537","DOI":"10.1016\/j.intimp.2022.109537","article-title":"Inhibition of neutrophil elastase prevents cigarette smoke exposure-induced formation of neutrophil extracellular traps and improves lung function in a mouse model of chronic obstructive pulmonary disease","volume":"114","author":"Wang","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"2026082009500867000_5.1.e002195.73","doi-asserted-by":"publisher","DOI":"10.3109\/08958378.2011.559603"},{"key":"2026082009500867000_5.1.e002195.74","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1080\/15412555.2017.1335697","article-title":"A Randomized, Placebo-Controlled Phase 2 Trial of CNTO 6785 in Chronic Obstructive Pulmonary Disease","volume":"14","author":"Eich","year":"2017","journal-title":"COPD"},{"key":"2026082009500867000_5.1.e002195.75","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09046-8"},{"key":"2026082009500867000_5.1.e002195.76","first-page":"39","article-title":"Eosinophilic airway inflammation in COPD","volume":"1","author":"Saha","year":"2006","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2026082009500867000_5.1.e002195.77","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00633-2019","article-title":"Blood eosinophil counts in COPD patients compared to controls","volume":"54","author":"Kolsum","year":"2019","journal-title":"Eur Respir J"},{"key":"2026082009500867000_5.1.e002195.78","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00427-2018"},{"key":"2026082009500867000_5.1.e002195.79","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12931-020-1279-4","article-title":"The stability of blood eosinophils in chronic obstructive pulmonary disease","volume":"21","author":"Long","year":"2020","journal-title":"Respir Res"},{"key":"2026082009500867000_5.1.e002195.80","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.04.010"},{"key":"2026082009500867000_5.1.e002195.81","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S2213-2600(15)00106-X","article-title":"Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials","volume":"3","author":"Pascoe","year":"2015","journal-title":"Lancet Respir Med"},{"key":"2026082009500867000_5.1.e002195.82","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S2213-2600(18)30006-7","article-title":"Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials","volume":"6","author":"Bafadhel","year":"2018","journal-title":"Lancet Respir Med"},{"key":"2026082009500867000_5.1.e002195.83","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1513\/AnnalsATS.202406-597OC","article-title":"Role of Monoclonal Antibodies in the Management of Eosinophilic Chronic Obstructive Pulmonary Disease: A Meta-Analysis of Randomized Controlled Trials","volume":"22","author":"Mohamed","year":"2025","journal-title":"Ann Am Thorac Soc"},{"key":"2026082009500867000_5.1.e002195.84","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2023.11.040"},{"key":"2026082009500867000_5.1.e002195.85","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/resp.12724","article-title":"Prevalence of blood eosinophilia in hospitalized patients with acute exacerbation of COPD","volume":"21","author":"Hasegawa","year":"2016","journal-title":"Respirology"},{"key":"2026082009500867000_5.1.e002195.86","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S2213-2600(24)00299-6","article-title":"Treating eosinophilic exacerbations of asthma and COPD with benralizumab (ABRA): a double-blind, double-dummy, active placebo-controlled randomised trial","volume":"13","author":"Ramakrishnan","year":"2025","journal-title":"Lancet Respir Med"},{"key":"2026082009500867000_5.1.e002195.87","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2500012","article-title":"Mepolizumab for COPD with Eosinophilic Phenotype following Hospitalization","volume":"4","author":"Flynn","year":"2025","journal-title":"NEJM Evidence"},{"key":"2026082009500867000_5.1.e002195.88","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jacig.2022.09.001","article-title":"Rethinking blood eosinophil counts: Epidemiology, associated chronic diseases, and increased risks of cardiovascular disease","volume":"1","author":"Pongdee","year":"2022","journal-title":"J Allergy Clin Immunol Glob"},{"key":"2026082009500867000_5.1.e002195.89","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1164\/rccm.202201-0209PP","article-title":"Blood Eosinophils and Chronic Obstructive Pulmonary Disease: A Global Initiative for Chronic Obstructive Lung Disease Science Committee 2022 Review","volume":"206","author":"Singh","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2026082009500867000_5.1.e002195.90","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1164\/rccm.202105-1162LE","article-title":"Blood Eosinophil Counts in Chronic Obstructive Pulmonary Disease: Adding Within-Day Variability to the Equation","volume":"205","author":"Van Rossem","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2026082009500867000_5.1.e002195.91","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3949\/ccjm.90a.22072","article-title":"Measuring exhaled nitric oxide when diagnosing and managing asthma","volume":"90","author":"Sen","year":"2023","journal-title":"CCJM"},{"key":"2026082009500867000_5.1.e002195.92","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1080\/02770903.2020.1744641","article-title":"The asthma evidence base: a call for core outcomes in interventional trials","volume":"58","author":"Tejwani","year":"2021","journal-title":"J Asthma"},{"key":"2026082009500867000_5.1.e002195.93","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2021.03.022"},{"key":"2026082009500867000_5.1.e002195.94","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2007.10.025"},{"key":"2026082009500867000_5.1.e002195.95","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0910061"},{"key":"2026082009500867000_5.1.e002195.96","doi-asserted-by":"publisher","DOI":"10.1513\/pats.200805-041HR"},{"key":"2026082009500867000_5.1.e002195.97","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201211-1987OC"},{"key":"2026082009500867000_5.1.e002195.98","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02091-2025"},{"key":"2026082009500867000_5.1.e002195.99","first-page":"510","article-title":"The Effectiveness and Value of Biologic Therapies for the Treatment of Uncontrolled Asthma","volume":"25","author":"Tice","year":"2019","journal-title":"J Manag Care Spec Pharm"},{"key":"2026082009500867000_5.1.e002195.100","doi-asserted-by":"crossref","DOI":"10.1111\/pai.13942","article-title":"Cost-effectiveness of omalizumab for the treatment of severe pediatric allergic asthma-Results of a real-life study in Spain","volume":"34","author":"Nieto-Cid","year":"2023","journal-title":"Pediatr Allergy Immunol"},{"key":"2026082009500867000_5.1.e002195.101","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-018-0658-x"},{"key":"2026082009500867000_5.1.e002195.102","doi-asserted-by":"crossref","first-page":"100502","DOI":"10.1016\/j.waojou.2020.100502","article-title":"Biologics and global burden of asthma: A worldwide portrait and a call for action","volume":"14","author":"Caminati","year":"2021","journal-title":"World Allergy Organ J"},{"key":"2026082009500867000_5.1.e002195.103","doi-asserted-by":"publisher","DOI":"10.1016\/j.pec.2011.02.017"},{"key":"2026082009500867000_5.1.e002195.104","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2147\/COPD.S343108","article-title":"The Importance of Self-Management in the Context of Personalized Care in COPD","volume":"Volume 17","author":"Cravo","year":"2022","journal-title":"COPD"},{"key":"2026082009500867000_5.1.e002195.105","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrtlng.2010.02.003"},{"key":"2026082009500867000_5.1.e002195.106","doi-asserted-by":"crossref","DOI":"10.1038\/s41533-017-0046-6","article-title":"Self-management behaviour and support among primary care COPD patients: cross-sectional analysis of data from the Birmingham Chronic Obstructive Pulmonary Disease Cohort","volume":"27","author":"Khan","year":"2017","journal-title":"NPJ Prim Care Respir Med"},{"key":"2026082009500867000_5.1.e002195.107","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02583-2021","article-title":"Asthma remission: what is it and how can it be achieved?","volume":"60","author":"Thomas","year":"2022","journal-title":"Eur Respir J"},{"key":"2026082009500867000_5.1.e002195.108","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202406-1254CI"},{"key":"2026082009500867000_5.1.e002195.109","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02284-5"},{"key":"2026082009500867000_5.1.e002195.110","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201208-1414OC"},{"key":"2026082009500867000_5.1.e002195.111","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2013.02.032"},{"key":"2026082009500867000_5.1.e002195.112","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2024.107720"},{"key":"2026082009500867000_5.1.e002195.113","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1403291"},{"key":"2026082009500867000_5.1.e002195.114","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60988-X"},{"key":"2026082009500867000_5.1.e002195.115","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.jaip.2022.11.043","article-title":"Baseline FeNO Independently Predicts the Dupilumab Response in Patients With Moderate-to-Severe Asthma","volume":"11","author":"Pavord","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2026082009500867000_5.1.e002195.116","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/j.jaip.2021.01.008","article-title":"The relationship between FeNO and effectiveness of mepolizumab and benralizumab in severe eosinophilic asthma","volume":"9","author":"Hearn","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2026082009500867000_5.1.e002195.117","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jaip.2018.04.043","article-title":"Omalizumab Effectiveness by Biomarker Status in Patients with Asthma: Evidence From PROSPERO, A Prospective Real-World Study","volume":"7","author":"Casale","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2026082009500867000_5.1.e002195.118","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00560-2021","article-title":"Evaluation of sputum eosinophil count as a predictor of treatment response to mepolizumab","volume":"8","author":"Pavord","year":"2022","journal-title":"ERJ Open Res"},{"key":"2026082009500867000_5.1.e002195.119","doi-asserted-by":"publisher","DOI":"10.1136\/thorax-2022-219781"},{"key":"2026082009500867000_5.1.e002195.120","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2024.01.031"},{"key":"2026082009500867000_5.1.e002195.121","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2024.03.023"},{"key":"2026082009500867000_5.1.e002195.122","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1106469"},{"key":"2026082009500867000_5.1.e002195.123","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.chest.2023.02.009","article-title":"CT Mucus Score and 129Xe MRI Ventilation Defects After 2.5 Years\u2019 Anti-IL-5R\u03b1 in Eosinophilic Asthma","volume":"164","author":"McIntosh","year":"2023","journal-title":"Chest"},{"key":"2026082009500867000_5.1.e002195.124","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/j.chest.2020.04.056","article-title":"Effects of Anti-T2 Biologic Treatment on Lung Ventilation Evaluated by MRI in Adults With Prednisone-Dependent Asthma","volume":"158","author":"Svenningsen","year":"2020","journal-title":"Chest"}],"container-title":["BMJ Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjmed-2025-002195","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:50:26Z","timestamp":1787244626000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjmedicine.bmj.com\/lookup\/doi\/10.1136\/bmjmed-2025-002195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":124,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,8,20]]},"published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1136\/bmjmed-2025-002195"],"URL":"https:\/\/doi.org\/10.1136\/bmjmed-2025-002195","relation":{},"ISSN":["2754-0413"],"issn-type":[{"value":"2754-0413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]}}}